Drug Profile
Masitinib - AB Science
Alternative Names: AB-07105; AB-1010; Alsitek; Masican; Masipro; Masitinib mesilate; Masitinib mesylate; MasivieraLatest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator AB Science
- Class Anti-inflammatories; Antiasthmatics; Antidementias; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antirheumatics; Antivirals; Benzamides; Mood stabilisers; Nootropics; Piperazines; Pyridines; Small molecules; Thiazoles; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Colony stimulating factor inhibitors; Coronavirus-3C-like-proteinase inhibitors; Endopeptidase Clp inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Lyn protein-tyrosine kinase inhibitors; Macrophage colony-stimulating factor receptor modulators; Mast cell inhibitors; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-fyn modulators; Type 3 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Amyotrophic lateral sclerosis
- Phase III Alzheimer's disease; Asthma; Colorectal cancer; Gastrointestinal stromal tumours; Mastocytosis; Multiple myeloma; Multiple sclerosis; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer
- Phase II/III Crohn's disease; Ovarian cancer
- Phase II Breast cancer; Chronic obstructive pulmonary disease; COVID 2019 infections; Head and neck cancer; Non-small cell lung cancer; Parkinson's disease
- Phase I/II Gastric cancer; Glioblastoma; Liver cancer; Oesophageal cancer
- No development reported Psoriasis; Stroke
- Discontinued Malignant melanoma; Mood disorders; Progressive supranuclear palsy; Rheumatoid arthritis
Most Recent Events
- 03 Apr 2024 Health Canada grants eligibility for reconsideration request for masitinib in Amyotrophic lateral sclerosis
- 13 Mar 2024 Pharmacodynamics data from preclinical trial in Neurodegenerative disorders released by AB Science
- 29 Feb 2024 AB Science announces intention of conditional approval of Masitinib for Amyotrophic lateral sclerosis (ALS) in EU and Canada